Daniel Stauder
Stock Analyst at Citizens
(2.39)
# 2,479
Out of 5,182 analysts
23
Total ratings
40.91%
Success rate
5.04%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daniel Stauder
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LMAT LeMaitre Vascular | Maintains: Market Outperform | $113 → $118 | $114.36 | +3.18% | 5 | Feb 26, 2026 | |
| ATRC AtriCure | Maintains: Market Outperform | $60 → $52 | $29.72 | +74.97% | 7 | Feb 18, 2026 | |
| STXS Stereotaxis | Initiates: Market Outperform | $4 | $2.03 | +97.04% | 1 | Dec 16, 2025 | |
| AORT Artivion | Maintains: Market Outperform | $47 → $53 | $37.72 | +40.51% | 7 | Nov 7, 2025 | |
| STIM Neuronetics | Maintains: Market Outperform | $3 → $7 | $1.42 | +392.96% | 1 | Mar 5, 2025 | |
| AXON Axon Enterprise | Reiterates: Market Outperform | $725 | $402.85 | +79.97% | 1 | Feb 26, 2025 | |
| AVNS Avanos Medical | Reiterates: Market Perform | n/a | $24.62 | - | 1 | May 7, 2024 |
LeMaitre Vascular
Feb 26, 2026
Maintains: Market Outperform
Price Target: $113 → $118
Current: $114.36
Upside: +3.18%
AtriCure
Feb 18, 2026
Maintains: Market Outperform
Price Target: $60 → $52
Current: $29.72
Upside: +74.97%
Stereotaxis
Dec 16, 2025
Initiates: Market Outperform
Price Target: $4
Current: $2.03
Upside: +97.04%
Artivion
Nov 7, 2025
Maintains: Market Outperform
Price Target: $47 → $53
Current: $37.72
Upside: +40.51%
Neuronetics
Mar 5, 2025
Maintains: Market Outperform
Price Target: $3 → $7
Current: $1.42
Upside: +392.96%
Axon Enterprise
Feb 26, 2025
Reiterates: Market Outperform
Price Target: $725
Current: $402.85
Upside: +79.97%
Avanos Medical
May 7, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $24.62
Upside: -